PRAXOBio
ai-native drug discovery — pre-launch
artificial intelligence · translational medicine · unmet need

Medicines the old process
couldn’t reach — built with AI.

PraxoBio applies artificial intelligence across the entire drug discovery pipeline — from target identification through candidate optimization — in pursuit of treatments for diseases that still have no adequate therapy.

early access
no spam, ever — a single email when we launch.
the process
how it works

Not a straight line — a loop.

AI CORE continuous learning 01 Target ID AI mines biology for validated targets 02 AI Design Generative models propose novel molecules 03 Optimization Potency, safety & developability refined 04 Preclinical Data-driven, focused evaluation 05 Clinic AI-informed trial design

Every stage feeds the AI core, and the AI core feeds every stage back — findings from optimization reshape target selection, preclinical signals redirect design, before anything reaches the clinic.

the problem

Fewer than 5% of the roughly ten thousand identified rare and complex diseases have an FDA-approved treatment. For the other 95%, the science hasn’t moved fast enough — not because the biology is unsolvable, but because the process to get there has been too slow, too costly, and too narrow to reach most of them.

PraxoBio exists to change that ratio — using AI to widen the aperture of what’s worth pursuing, and shorten the distance between a validated target and a patient who’s been waiting.

~10,000
identified rare & complex diseases
<5%
with an approved treatment today
1 in 10
Americans affected by a rare disease